Report Shows Diabetes Drug Best Sellers

| Nov 17, 2013

"Top 100 Selling Drugs Through September," an article in the October 31 issue of Medscape (sourced from IMS Health), shows that while eight diabetes medications are in the nation's top 100 best-selling drugs, none are in the top 10.

The report tracked sales and prescription numbers for the top drugs from October 1, 2012 through September 30, 2013.

The eight drugs named below are listed according to the number of their position in the sales rankings and their total dollar sales:

14. Januvia, $2.825 billion

15. Lantus Solostar: $2.779 billion

18. Lantus: $2.515 billion

34. Novolog: $1.33 billion

35. Novolog Flexpen: $1.317 billion

39. Humalog: $1.143 billion

47. Janument: $967 million

90. Actos: $130 million

Prescription Numbers

The report also ranked the top 100 drugs by number of prescriptions over the same one-year period, both new and refills. There were 12 diabetes drugs in the category.

10. Lantus: 9.5 million

13. Lantus Solostar: 9.053 million

15. Januvia: 8,746 million

30. Levemir: 4.75 million

35. Novolog: 4.2 million

40. Novolog Flexpen: 3.976 million

43. Humalog: 3.568 million

49. Janumet: 3.26 million

65. Humalog Kwikpen: 2.234 million

73. Onglyza: 1.78 million

77. Victoza: 1.684 million

100. Humulin: 1.217 million

The top prescribed non-diabetes drug was Crestor, with 23.737 million prescriptions.

The Top 10 Overall

The 10 top-selling drugs for the reported sales period were:

1. Abilify: $6.391 billion

2. Nexium: $6.087 billion

3. Cymbalta: $5.432 billion

4. Humira: $5.352 billion

5. Crestor: $5.318 billion

6. Advair Diskus: $5.114 billion

7. Enbrel: $4.673 billion

8. Remicade: $4.058 billion

9. Copaxone: $3.789 billion

10. Neulasta: $3.358 billion

 

Click Here To View Or Post Comments

Categories: Diabetes Drugs, Top Selling Drugs


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated

Latest Top Selling Drugs Articles

Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.